Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in HER2-positive breast cancer with brain metastases
2015-003103-27Phase 2Terminated
- Sponsor
- University of Liverpool
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in breast cancer and brain metastases, sponsored by University of Liverpool. Primary endpoint: Change in FLT uptake by PET between baseline and Day 14. Started Dec 2016; status: terminated.
02
Drugs
buparlisib
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2015-003103-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003103-27.